Rheumatology and immunology research最新文献

{"title":"Understanding the roles of the microbiome in autoimmune rheumatic diseases.","authors":"Abhimanyu Amarnani, Gregg J Silverman","doi":"10.2478/rir-2023-0027","DOIUrl":"10.2478/rir-2023-0027","url":null,"abstract":"<p><p>The gut microbiome represents a potential promising therapeutic target for autoimmune diseases. This review summarizes the current knowledge on the links between the gut microbiome and several autoimmune rheumatic diseases including rheumatoid arthritis (RA), systemic lupus erythematosus (SLE) spondyloarthropathies (SpA), Sjogren's syndrome (SS), and systemic sclerosis (SSc). Evidence from studies of RA and SLE patients suggests that alterations in the gut microbiome composition and function contribute to disease development and progression through increased gut permeability, with microbes and microbial metabolites driving an excessive systemic activation of the immune system. Also, there is growing evidence that gut dysbiosis and subsequent immune cell activation may contribute to disease pathogenesis in SpA and SS. For SSc, there are fewer, but these are still informative, reports on alterations in the gut microbiome. In general, the complex interplay between the microbiome and the immune system is still not fully understood. Here we discuss the current knowledge of the link between the gut microbiome and autoimmune rheumatic diseases, highlighting potentially fertile areas for future research and make considerations on the potential benefits of strategies that restore gut microbiome homeostasis.</p>","PeriodicalId":74736,"journal":{"name":"Rheumatology and immunology research","volume":"4 4","pages":"177-187"},"PeriodicalIF":0.0,"publicationDate":"2023-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10729600/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138833428","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correlations of baseline neutrophil-lymphocyte ratio with prognosis of patients with lupus nephritis: A single-center experience.","authors":"Yi Chen, Xue Wu, Xiaomei Chen, Mengmeng Li, Cainan Luo, Yamei Shi, Jing Li, Lijun Wu","doi":"10.2478/rir-2023-0029","DOIUrl":"https://doi.org/10.2478/rir-2023-0029","url":null,"abstract":"<p><strong>Objective: </strong>We aimed to evaluate the correlations among the neutrophil-to-lymphocyte ratio (NLR), lupus nephritis (LN) clinical characteristics, and renal prognosis of patients with LN.</p><p><strong>Methods: </strong>We enrolled 122 patients who were diagnosed with LN at the Rheumatology Department of the People's Hospital, Xinjiang Uygur Autonomous Region from January 2013 to April 2022. We determined the occurrence of renal adverse events in patients with LN by reviewing medical records and follow-up data. Correlations were analyzed using the Spearman test, and the quartile method was applied to classify all of the 122 patients who had completed follow-up into low, medium, and high NLR groups. The Kaplan-Meier survival curve was used to conduct survival analysis, and Cox regression analyses were used to explore possible potential risk factors.</p><p><strong>Results: </strong>The baseline NLR of patients with LN was positively correlated with C-reactive protein (CRP), serum creatinine, blood urea nitrogen, and systemic lupus erythematosus disease activity index scores (<i>P</i> < 0.05) and negatively correlated with estimated glomerular filtration rate (eGFR) and serum albumin (<i>P</i> < 0.05). Patients who completed follow-up were divided into three NLR groups based on their NLR values: 30 in the low (NLR ≤ 2.21), 62 in the medium (NLR > 2.21 and NLR ≤ 6.17), and 30 in the high NLR group (NLR > 6.17). The patient survival time before developing poor renal prognosis was significantly different among the three groups (<i>P</i> < 0.05). High NLR (hazard ratio [HR] = 3.453, 95% confidence interval [CI]: 1.260-9.464), CRP (HR = 1.009, 95% CI: 1.002-1.017), eGFR (HR = 0.979, 95% CI: 0.963-0.995), and 24-h proteinuria values (HR = 1.237, 95% CI: 1.025-1.491) as well as anti-double stranded DNA antibody positivity (HR = 3.056, 95% CI:1.069-8.736) were independent risk factors associated with a poor renal prognosis for patients with LN.</p><p><strong>Conclusion: </strong>The baseline NLR in peripheral blood can be used as a reference index for evaluating renal function and disease activity in patients with LN, and a high NLR has predictive value for the prognosis of patients with LN.</p>","PeriodicalId":74736,"journal":{"name":"Rheumatology and immunology research","volume":"4 4","pages":"196-203"},"PeriodicalIF":0.0,"publicationDate":"2023-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10729594/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138833426","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identification and functional prediction of long non-coding RNA and mRNA related to connective tissue disease-associated interstitial lung diseases.","authors":"Fei Dai, Yixi He, Tianyi Lei, Yi Jiang, Quanbo Zhang, Yufeng Qing","doi":"10.2478/rir-2023-0030","DOIUrl":"https://doi.org/10.2478/rir-2023-0030","url":null,"abstract":"<p><strong>Objective: </strong>Recently, the role of long non-coding RNA (lncRNA) in rheumatic immune diseases has attracted widespread attention. However, knowledge of lncRNA in connective tissue disease-associated interstitial lung disease (CTD-ILD) is limited. This study explored the expression profile and possible mechanisms of lncRNA and mRNA in peripheral blood mononuclear cells (PBMCs) of CTD-ILD patients, especially systemic sclerosis (SSc)-ILD and rheumatoid arthritis (RA)-ILD.</p><p><strong>Methods: </strong>LncRNA microarray analysis identified 240 diferentially expressed lncRNAs and 218 diferentially expressed mRNA in the CTD-ILD group and the connective tissue disease without associated interstitial lung disease (CTD-NILD) group. The bioinformatics analysis of diferential genes has identified several important biological processes and signal pathways, including nuclear factor kappa B (NF-kappa B) signaling pathway, interleukin 17 (IL-17) signaling pathway, B cell receptor signaling pathway. Relative expression levels of five diferentially expressed lncRNAs and one mRNA in 120 SSc and RA patients with or without ILD were detected by quantitative reverse-transcription (PCR).</p><p><strong>Results: </strong>The <i>ENST00000604692</i> expression level was significantly higher in the ILD than the without interstitial lung disease (NILD) group; <i>T311354</i> and arginase-1 were significantly higher in SSc than RA group.</p><p><strong>Conclusion: </strong>These data suggest that the specific profile of lncRNA in PBMCs of CTD-ILD patients and the potential signal pathways related to the pathogenesis of CTD-ILD, which may provide newfound insights for the diagnosis and treatment of CTD-ILD patients.</p>","PeriodicalId":74736,"journal":{"name":"Rheumatology and immunology research","volume":"4 4","pages":"204-215"},"PeriodicalIF":0.0,"publicationDate":"2023-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10729597/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138833427","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Overcoming rheumatoid arthritis challenges: Ensuring timely referral to rheumatologists in resource-scarce countries.","authors":"Anum Khan, Babur Salim, Shahida Perveen, Saba Samreen, Haris Gul, Amjad Nasim","doi":"10.2478/rir-2023-0033","DOIUrl":"https://doi.org/10.2478/rir-2023-0033","url":null,"abstract":"","PeriodicalId":74736,"journal":{"name":"Rheumatology and immunology research","volume":"4 4","pages":"222-224"},"PeriodicalIF":0.0,"publicationDate":"2023-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10729589/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138835951","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Low-dose interleukin-2 therapy in systemic lupus erythematosus.","authors":"Antonio La Cava","doi":"10.2478/rir-2023-0021","DOIUrl":"10.2478/rir-2023-0021","url":null,"abstract":"<p><p>In systemic lupus erythematosus (SLE), T regulatory cells (T_regs) contribute to the inhibition of autoimmune responses by suppressing self-reactive immune cells. Interleukin (IL)-2 plays an essential role in the generation, function and homeostasis of the T_regs and is reduced in SLE. Several clinical studies, including randomized trials, have shown that low-dose IL-2 therapy in SLE patients is safe and effective and can reduce disease manifestations. This review discusses the rationale for the use of low-dose IL-2 therapy in SLE, the clinical responses in patients, and the effects of this therapy on different types of T cells. Considerations are made on the current and future directions of use of low-dose IL-2 regimens in SLE.</p>","PeriodicalId":74736,"journal":{"name":"Rheumatology and immunology research","volume":"4 3","pages":"150-156"},"PeriodicalIF":0.0,"publicationDate":"2023-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10538619/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41180596","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"East-Asian lupus nephritis in the Hopkins Lupus Cohort.","authors":"Michelle Petri, Chenglong Fang, Daniel W Goldman","doi":"10.2478/rir-2023-0022","DOIUrl":"10.2478/rir-2023-0022","url":null,"abstract":"<p><strong>Background and objective: </strong>East Asian systemic lupus erythematosus (SLE) is under represented in lupus cohorts outside of East Asia. We asked whether lupus nephritis was more common and more severe in East Asians than in other ethnicities in a large United States SLE cohort.</p><p><strong>Methods: </strong>The Hopkins Lupus Cohort, a longitudinal cohort of 2802 patients (53.5% Caucasian, 39.2% African-American, 3.2% East Asian) was studied. The SLICC/ACR Damage Index was used to assess renal outcomes. Results: East Asian patients had the same prevalence of lupus nephritis as African-Americans and both were higher than Caucasians. East Asians were not significantly different in frequency of end stage kidney disease compared with African-Americans. East Asians were more likely than Caucasians to have anti-Sm, low C3 and low C4. East Asians were more likely than African-Americans to have low C3 and low C4.</p><p><strong>Conclusion: </strong>East Asians living in the United States were more likely to have lupus nephritis than Caucasians. Poor outcomes such as end stage kidney disease occurred at an equal frequency in East Asians as in African-Americans. Lupus nephritis was both more frequent and more severe in East Asians than in African-Americans.</p>","PeriodicalId":74736,"journal":{"name":"Rheumatology and immunology research","volume":"4 3","pages":"157-161"},"PeriodicalIF":0.0,"publicationDate":"2023-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10538617/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41157333","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Improve quality of patient care for systemic lupus erythematosus in China by enhancing the construction of Centers of Excellence.","authors":"Mengtao Li, Xinping Tian, Qian Wang, Jiuliang Zhao, Junyan Qian, Chengde Yang, Cibo Huang, Hui Luo, Huji Xu, Jieruo Gu, Jin Lin, Lijun Wu, Miaojia Zhang, Niansheng Yang, Pinting Yang, Shengyun Liu, Wei Wei, Xinwang Duan, Yi Liu, Zhiyi Zhang, Zhuoli Zhang, Yan Zhao, Xiaofeng Zeng","doi":"10.2478/rir-2023-0023","DOIUrl":"10.2478/rir-2023-0023","url":null,"abstract":"","PeriodicalId":74736,"journal":{"name":"Rheumatology and immunology research","volume":"4 3","pages":"162-166"},"PeriodicalIF":0.0,"publicationDate":"2023-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10538611/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41159623","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Active pattern on nailfold capillaroscopy in a patient with systemic sclerosis.","authors":"Wenjing Ye,&nbsp;Ling Cao,&nbsp;Yingzi Zhou,&nbsp;Yu Xue,&nbsp;Weiguo Wan,&nbsp;Hejian Zou,&nbsp;Xiaoxia Zhu","doi":"10.2478/rir-2023-0025","DOIUrl":"10.2478/rir-2023-0025","url":null,"abstract":"A 65-year-old man presented with a two-year history of Raynaud’s phenomenon (RP) and a ten-month history of rapidly progress of skin swelling and hardening. Autoantibody testing revealed positivity for antinuclear antibodies (1: 1000) and anti-Scl70 antibodies, baseline serum creatine and blood pressure were normal. Nailfold capillaroscopy (NC) examination demonstrated decreased capillary density, along with enlarged (giant) capillaries, perivascular effusion, hemor - rhage, and slowed blood flow (Figure 1A). Upon the diagno - sis of diffuse cutaneous systemic sclerosis (SSc), the patient sought care at a local hospital, where he initiated treatment with prednisone (30 mg/d). However, he returned to our institution two weeks later, due to the possibility of a scleroderma renal crisis with weakness, elevated blood pressure, chest distress, nausea and increased serum creatinine. The aberrant blood capillaries observed in patients with SSc (","PeriodicalId":74736,"journal":{"name":"Rheumatology and immunology research","volume":"4 3","pages":"171-172"},"PeriodicalIF":0.0,"publicationDate":"2023-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10538595/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41158953","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lupus clinical trials and the promise of future therapies.","authors":"Leila Khalili,&nbsp;Wei Tang,&nbsp;Anca D Askanase","doi":"10.2478/rir-2023-0018","DOIUrl":"https://doi.org/10.2478/rir-2023-0018","url":null,"abstract":"E-mail: ada20@cumc.columbia.edu; https://orcid.org/0000-0003-4597-5023 Several successful phase 3 trials and the approval of these new therapies in systemic lupus erythematosus (SLE), have resulted in increased interest in drug development in lupus.[1-3] Despite the recent approval of new therapies for SLE and lupus nephritis (LN) there is still an urgent need for advanced therapies as response rates are still in the 50%–60% range.[4–6]","PeriodicalId":74736,"journal":{"name":"Rheumatology and immunology research","volume":"4 3","pages":"109-114"},"PeriodicalIF":0.0,"publicationDate":"2023-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10538598/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41161846","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A rare condition that mimic myopathy: Late-onset glutaric acidaemia type II.","authors":"Jianwen Liu,&nbsp;Chenmin Wu,&nbsp;Fei Gao,&nbsp;Qing Yan","doi":"10.2478/rir-2023-0026","DOIUrl":"10.2478/rir-2023-0026","url":null,"abstract":"A 21-year-old woman visited the emergency department because of muscle weakness and hypoglycaemic coma. She had a 1-year history of exercise intolerance, myalgia and muscle weakness. Her body weight decreased from 65 to 40 kg. Physical examination at admission revealed neck and proximal limb muscle weakness (manual muscle testing 8 [MMT8] score, 26 points) accompanied by severe muscle atrophy. Her serum creatine kinase (CK) and lactate dehydrogenase (LDH) levels were 15514 U/L (reference interval [RI]: 40–200 U/L) and 1438 U/L (RI: 120–250 U/L), respectively, and serum myoglobin (Mb) level was 758.5 ng/mL. Abdominal ultrasonography showed severe hepatic steatosis and electromyography revealed features of myopathy. Magnetic resonance imaging (MRI) of her thigh muscles was normal. The patient was diagnosed with idiopathic inflammatory myositis (IIM), and she was treated with 60 mg/day methylprednisolone (MP) and coenzyme Q10 (10 mg, 3 times/day).","PeriodicalId":74736,"journal":{"name":"Rheumatology and immunology research","volume":"4 3","pages":"173-175"},"PeriodicalIF":0.0,"publicationDate":"2023-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10538596/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41174384","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}